Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark...
Kimberly-Clark CEO Mike Hsu told CNBC’s Jim Cramer that his company’s planned acquisition of Tylenol maker Kenvue will create value for shareholders, even as the pain...
Kenvue’s interim CEO is defending Tylenol’s safety after President Donald J. Trump and Health Secretary Robert F. Kennedy Jr. linked the pain reliever to autism and...
